International consensus guidance statement on the management and treatment of IgG4-related disease

Arthritis and Rheumatology

Volumn 67, Issue 7, 2015, Pages 1688-1699

  Khosroshahi, A ^a   Wallace, Z S ^b   Crowe, J L ^c   Akamizu, T ^d   Azumi, A ^e   Carruthers, M N ^f   Chari, S T ^g   Della Torre, E ^h   Frulloni, L ⁱ   Goto, H ^j   Hart, P A ^k   Kamisawa, T ^l   Kawa, S ^m   Kawano, M ⁿ   Kim, M H ^o   Kodama, Y ^p   Kubota, K ^q   Lerch, M M ^r   Lohr M ^s   Masaki, Y ^t   Matsui, S ^u   Mimori, T ^p   Nakamura, S ^v   Nakazawa, T ^w   Ohara, H ^w   Okazaki, K ^x   Ryu, J H ^g   Saeki, T ^y   Schleinitz, N ^z   Shimatsu, A ^aa   Shimosegawa, T ^ab   Takahashi, H ^ac   Takahira, M ⁿ   Tanaka, A ^ad   Topazian, M ^g   Umehara, H ^t   Webster, G J ^ae   Witzig, T E ^g   Yamamoto, M ^ac   Zhang, W ^af   Chiba, T ^p   Stone, J H ^b   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e KOBE KAISEI HOSPITAL   (Japan)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MAYO CLINIC   (United States)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j TOKYO MEDICAL UNIVERSITY   (Japan)

^k THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^l TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^m SHINSHU UNIVERSITY   (Japan)

ⁿ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^o University of Ulsan College of Medicine   (South Korea)

^p KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^r Medical University of Greifswald   (Germany)

^s KAROLINSKA INSTITUTE   (Sweden)

^t KANAZAWA MEDICAL UNIVERSITY   (Japan)

^u UNIVERSITY OF TOYAMA   (Japan)

^v KYUSHU UNIVERSITY HOSPITAL   (Japan)

^w NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^x KANSAI MEDICAL UNIVERSITY   (Japan)

^y NAGAOKA RED CROSS HOSPITAL   (Japan)

^z AIX MARSEILLE UNIVERSITY   (France)

^aa NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^ab TOHOKU UNIVERSITY   (Japan)

^ac SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ad TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ae UNIVERSITY COLLEGE LONDON   (United Kingdom)

^af PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; BIOLOGICAL PRODUCT; GLUCOCORTICOID; IMMUNOGLOBULIN G;

ARTICLE; BIOPSY; CORTICOSTEROID THERAPY; DRUG CONTRAINDICATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN G4 RELATED DISEASE; LABORATORY; MAINTENANCE THERAPY; PRIORITY JOURNAL; RADIOLOGY; RELAPSE; REMISSION; SEROLOGY; AUTOIMMUNE DISEASES; CONSENSUS DEVELOPMENT; IMMUNOLOGY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 84930021856     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39132     Document Type: Article

References (78)

1. Stone JH, Zen Y, Deshpande V., IgG4-related disease. N Engl J Med 2012; 366: 539-51.
2. Carruthers MN, Stone JH, Khosroshahi A., The latest on IgG4-RD: a rapidly emerging disease. Curr Opin Rheumatol 2012; 24: 60-9.
3. Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, et al., Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64: 3061-7.
4. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al., A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.
5. Cheuk W, Chan JK., IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 2010; 17: 303-32.
6. Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, et al., Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol 2011; 15: 615-26.
7. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al., High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-8.
8. Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, et al., Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646-53.
9. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH., The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74: 14-8.
10. Takahira M, Ozawa Y, Kawano M, Zen Y, Hamaoka S, Yamada K, et al., Clinical aspects of IgG4-related orbital inflammation in a case series of ocular adnexal lymphoproliferative disorders. Int J Rheumatol 2012; 2012: 635473.
11. Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H., Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 2014; 21: 43-50.
12. Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al., Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 2010; 78: 1016-23.
13. Ebbo M, Grados A, Bernit E, Vely F, Boucraut J, Harle JR, et al., Pathologies associated with serum IgG4 elevation. Int J Rheumatol 2012; 2012: 602809.
14. Ryu JH, Horie R, Sekiguchi H, Peikert T, Yi ES., Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheumatol 2012; 2012: 232960.
15. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al., Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74: 190-5.
16. Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, et al., De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 2014; 134: 679-87.
17. Kamisawa T, Okamoto A, Funata N., Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 2005; 31: 28-31.
18. Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al., Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 2011; 50: 69-75.
19. Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, et al., The clinical course of patients with IgG4-related kidney disease. Kidney Int 2013; 84: 826-33.
20. 18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken) 2014; 66: 86-96.
21. Takahashi H, Yamashita H, Morooka M, Kubota K, Takahashi Y, Kaneko H, et al., The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease. Joint Bone Spine 2014; 81: 331-6.
22. Carruthers MN, Stone JH, Deshpande V, Khosroshahi A., Development of an IgG4-RD Responder Index. Int J Rheumatol 2012; 2012: 259408.
23. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al., Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30.
24. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al., International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-8.
25. Kawa S, Hamano H., Autoimmune pancreatitis and bile duct lesions. J Gastroenterol 2003; 38: 1201-3.
26. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al., Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-92.
27. Okazaki K, Kawa S, Kamisawa T, Ito T, Inui K, Irie H, et al., Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013. I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol 2014; 49: 567-88.
28. Moriyama M, Furukawa S, Kawano S, Goto Y, Kiyoshima T, Tanaka A, et al., The diagnostic utility of biopsies from the submandibular and labial salivary glands in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Int J Oral Maxillofac Surg 2014; 43: 1276-81.
29. Brenner I, Roth S, Puppe B, Wobser M, Rosenwald A, Geissinger E., Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression. Mod Pathol 2013; 26: 1568-76.
30. Wallace ZS, Carruthers MN, Khosroshahi A, Carruthers R, Shinagare S, Stemmer-Rachamimov A, et al., IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore) 2013; 92: 206-16.
31. Strehl JD, Hartmann A, Agaimy A., Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 2011; 64: 237-43.
32. Chang SY, Keogh KA, Lewis JE, Ryu JH, Cornell LD, Garrity JA, et al., IgG4-positive plasma cells in granulomatosis with polyangiitis (Wegener's): a clinicopathologic and immunohistochemical study on 43 granulomatosis with polyangiitis and 20 control cases. Hum Pathol 2013; 44: 2432-7.
33. Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C, et al., IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis 2012; 71: 390-3.
34. Yamamoto M, Takahashi H, Suzuki C, Tabeya T, Ohara M, Naishiro Y, et al., Analysis of serum IgG subclasses in Churg-Strauss syndrome: the meaning of elevated serum levels of IgG4. Intern Med 2010; 49: 1365-70.
35. Sato Y, Kojima M, Takata K, Morito T, Mizobuchi K, Tanaka T, et al., Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 2010; 63: 1084-9.
36. Okazaki K, Kawa S, Kamisawa T, Shimosegawa T, Tanaka M, working members of Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis. I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol 2010; 45: 249-65.
37. Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, et al., A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7: 1097-1103.
38. Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al., Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62: 1607-15.
39. Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al., Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24.
40. Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al., Necessity of early intervention for IgG4-related disease: delayed treatment induces fibrosis progression. Rheumatology (Oxford) 2013; 52: 679-83.
41. Mizushima I, Inoue D, Yamamoto M, Yamada K, Saeki T, Ubara Y, et al., Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther 2014; 16: R156.
42. Ohshima K, Sato Y, Yoshino T., A case of IgG4-related dacryoadenitis that regressed without systemic steroid administration. J Clin Exp Hematop 2013; 53: 53-6.
43. Stone JH, Patel VI, Oliveira GR, Stone JR., Case 38-2012-a 60-year-old man with abdominal pain and aortic aneurysms. N Engl J Med 2012; 367: 2335-46.
44. Seki N, Yamazaki N, Kondo A, Nomura K, Himi T., Spontaneous regression of lung lesions after excision of the submandibular gland in a patient with chronic sclerosing sialadenitis. Auris Nasus Larynx 2012; 39: 212-5.
45. Takayama M, Hamano H, Ochi Y, Saegusa H, Komatsu K, Muraki T, et al., Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol 2004; 99: 932-7.
46. Miura H, Miyachi Y., IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis: a recurrent case after a 5-year history of spontaneous remission. JOP 2009; 10: 432-7.
47. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al., Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.
48. Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al., Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013. III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014; 49: 961-70.
49. Kanno A, Nishimori I, Masamune A, Kikuta K, Hirota M, Kuriyama S, et al, Research Committee on Intractable Diseases of Pancreas. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 2012; 41: 835-9.
50. Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al., Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7: 1089-96.
51. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, et al., IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56.
52. Ghazale A, Chari ST., Optimising corticosteroid treatment for autoimmune pancreatitis. Gut 2007; 56: 1650-2.
53. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al., Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-15.
54. Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al., Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104: 2295-306.
55. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al., Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771-6.
56. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH., Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91: 57-66.
57. Bosco JJ, Suan D, Varikatt W, Lin MW., Extra-pancreatic manifestations of IgG4-related systemic disease: a single-centre experience of treatment with combined immunosuppression. Intern Med J 2013; 43: 417-23.
58. Buechter M, Klein CG, Kloeters C, Schlaak JF, Canbay A, Gerken G, et al., Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4-associated cholangitis. Z Gastroenterol 2014; 52: 564-8.
59. Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB Jr, et al., Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc 2007; 82: 692-9.
60. Plaza JA, Garrity JA, Dogan A, Ananthamurthy A, Witzig TE, Salomao DR., Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol 2011; 129: 421-8.
61. Khosroshahi A, Bloch DB, Deshpande V, Stone JH., Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-62.
62. Topazian M, Witzig TE, Smyrk TC, Pulido JS, Levy MJ, Kamath PS, et al., Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6: 364-6.
63. Carruthers MN, Topazian M, Khosroshahi A, Witzig T, Wallace ZS, Hart P, et al., Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015. E-pub ahead of print.
64. Ghazale AH, Chari ST, Vege SS., Update on the diagnosis and treatment of autoimmune pancreatitis. Curr Gastroenterol Rep 2008; 10: 115-21.
65. Yoo JJ, Park JJ, Kang EH, Lee EB, Song YW, Go HJ, et al., Risk factors for the recurrence of IgG4-related sclerosing disease without autoimmune pancreatitis. J Clin Rheumatol 2011; 17: 392-4.
66. Chen H, Lin W, Wang Q, Wu Q, Wang L, Fei Y, et al., IgG4-related disease in a Chinese cohort: a prospective study. Scand J Rheumatol 2014; 43: 70-4.
67. Patel H, Khalili K, Kyoung KT, Yazdi L, Lee E, May G, et al., IgG4 related disease: a retrospective descriptive study highlighting Canadian experiences in diagnosis and management. BMC Gastroenterol 2013; 13: 168.
68. Kawakami H, Zen Y, Kuwatani M, Eto K, Haba S, Yamato H, et al., IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct. J Gastroenterol Hepatol 2010; 5: 1648-55.
69. Liu B, Li J, Yan LN, Sun HR, Liu T, Zhang ZX., Retrospective study of steroid therapy for patients with autoimmune pancreatitis in a Chinese population. World J Gastroenterol 2013; 19: 569-74.
70. Kawa S, Okazaki K, Kamisawa T, Kubo K, Ohara H, Hasebe O, et al., Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013. II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol 2014; 49: 765-84.
71. Kamisawa T, Chari ST, Lerch MM, Kim MH, Gress TM, Shimosegawa T., Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut 2013; 62: 1373-80.
72. Kamisawa T, Okamoto A, Wakabayashi T, Watanabe H, Sawabu N., Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol 2008; 43: 609-13.
73. Kim HM, Chung MJ, Chung JB., Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39: 555-60.
74. Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y., Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2011; 23: 146-52.
75. Uchida K, Yazumi S, Nishio A, Kusuda T, Koyabu M, Fukata M, et al., Long-term outcome of autoimmune pancreatitis. J Gastroenterol 2009; 44: 726-32.
76. Song Y, Liu QD, Zhou NX, Zhang WZ, Wang DJ., Diagnosis and management of autoimmune pancreatitis: experience from China. World J Gastroenterol 2008; 14: 601-6.
77. Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al., Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol 2011; 46: 696-704.
78. Caputo C, Bazargan A, McKelvie PA, Sutherland T, Su CS, Inder WJ., Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy. Pituitary 2014; 17: 251-6.